Search results
Results From The WOW.Com Content Network
September 26, 2024 at 9:05 AM. (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer ...
AstraZeneca plc (/ ˌæstrəˈzɛnəkə /) (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2][3][4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
The cash deal aimed at bolstering AstraZeneca's drugs pipeline values U.S.-listed Icosavax at $15 a share, plus up to $5 a share if certain milestones are met. ... RSV is a break from AstraZeneca ...
(Reuters) -Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci ...
Alexion Pharmaceuticals, Inc., an independent subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic ...
AstraZeneca has long been in the oncology and other disease spaces, but rose to popularity in recent years with the success of its COVID-19 vaccine.The company has since withdrawn the vaccine due ...
In March 2018, Compugen entered into an exclusive license agreement with MedImmune, the global biologics research arm of AstraZeneca to develop bi-specific and multi-specific immuno-oncology antibody products derived from one of Compugen's pipeline products. MedImmune has the right to develop multiple product under this license and is solely ...
Durvalumab, [8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).